Strategies for antiviral stockpiling for future influenza pandemics: A global epidemic-economic perspective

Journal of the Royal Society Interface

Volumn 8, Issue 62, 2011, Pages 1307-1313

  Carrasco, Luis R ^a   Lee, Vernon J ^a,b,c   Chen, Mark I ^a,d,e   Matchar, David B ^e,f,g   Thompson, James P ^e   Cook, Alex R ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Ministry of Defence Government of Singapore   (Singapore)

^c The Australian National University   (Australia)

^d TAN TOCK SENG HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

Antiviral drugs; Epidemic modelling; Health economics; Influenza pandemic; Uncertainty

Indexed keywords

ANTI-VIRAL DRUGS; EPIDEMIC MODELLING; HEALTH ECONOMICS; INFLUENZA PANDEMICS; UNCERTAINTY;

COMMERCE; COST EFFECTIVENESS; EPIDEMIOLOGY; HEALTH RISKS; INTERNATIONAL COOPERATION;

COSTS;

ANTIVIRUS AGENT;

ARTICLE; BRAZIL; CHINA; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; EPIDEMIC; GUATEMALA; HEALTH ECONOMICS; HUMAN; INDIA; INDONESIA; MORTALITY; NEW ZEALAND; PANDEMIC INFLUENZA; SINGAPORE; UNCERTAINTY; UNITED KINGDOM; UNITED STATES; ZIMBABWE;

ANTIVIRAL AGENTS; BASIC REPRODUCTION NUMBER; COMPUTER SIMULATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, ECONOMIC; PANDEMICS;

EID: 79960877419     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2010.0715     Document Type: Article

References (32)

1. Potter, C. W. 2001 A history of influenza. J. Appl. Microbiol. 91, 572-579. (doi:10.1046/j.1365-2672.2001.01492.x)
2. Hayden, F. G. 2001 Perspectives on antiviral use during pandemic influenza. Phil. Trans. R. Soc. Lond. B 356, 1877-1884. (doi:10.1098/rstb.2001. 1007)
3. Dhankhar, P., Dasbach,E. J.&Elbasha, E. H. 2009 Economics of stockpiling for an influenza pandemic. Lancet Infect. Dis. 9, 459-460. (doi:10.1016/S1473-3099(09)70183-5)
4. Ferguson, N. M., Cummings, D. A. T., Cauchemez, S., Fraser, C., Riley, S., Meeyai, A., Iamsirithaworn, S. & Burke, D. S. 2005 Strategies for containing anemerging influenza pandemic in Southeast Asia. Nature 437, 209-214. (doi:10.1038/nature04017)
5. Ferguson, N. M., Cummings, D. A. T., Fraser, C., Cajka, J. C., Cooley, P. C. & Burke, D. S. 2006 Strategies for mitigating an influenza pandemic. Nature 442, 448-452. (doi:10.1038/nature04795)
6. Germann, T. C., Kadau, K., Longini, I. M. & Macken, C. A. 2006 Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci. USA 103, 5935-5940. (doi:10.1073/pnas.0601266103)
7. Longini Jr, I. M., Halloran, M.E., Nizam,A.& Yang, Y. 2004 Containing pandemic influenza with antiviral agents. Am. J. Epidemiol. 159, 623-633. (doi:10.1093/aje/kwh092)
8. Sander, B., Nizam, A., Garrison, L. P., Postma, M. J., Halloran, M. E. & Longini, I. M. 2009 Economic Evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 12, 226-233. (doi:10.1111/ j.1524-4733.2008.00437.x)
9. Balicer, R. D., Huerta, M., Davidovitch, N. & Grotto, I. 2005 Cost-benefit of stockpiling drugs for influenza pandemic. Emerg. Infect. Dis. 11, 1280-1282. (Pubitemid 41045338)
10. Lee, V. J., Phua, K. H., Chen, M. I., Chow, A., Ma, S., Goh, K. T. & Leo, Y. S. 2006 Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerg. Infect. Dis. 12, 95-102. (Pubitemid 43143543)
11. Lugnér, A. K. & Postma, M. J. 2009 Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur. J. Public Health 19, 516-520.(doi:10.1093/eurpub/ckp119)
12. Siddiqui, M. R. & Edmunds, W. J. 2008 Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg. Infect. Dis. 2, 267-274. (doi:10.3201/eid1402.070478)
13. Lugnér, A. K., Mylius, S. D. & Wallinga, J. 2009 Dynamic versus static models in cost-effectiveness analyses of antiviral drug therapy to mitigate an influenza pandemic. Health Econ. 19, 518-531.
14. Anderson, R. M. & May, R. M. 1992 Infectious diseases of humans: dynamics & control. Oxford, UK: Oxford University Press.
15. Diekmann, O. & Heesterbeek, J. A. P. 2000 Mathematical epidemiology of infectious diseases. Chichester, UK:Wiley.
16. Roberts, M.G. 2007 The pluses and minuses of R0. J. R. Soc. Interface 4, 949-961. (doi:10.1098/rsif.2007.1031)
17. Fraser, C. et al. 2009 Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324, 1557-1561. (doi:10.1126/science.1176062)
18. Mills, C. E., Robins, J. M. & Lipsitch, M. 2004 Transmissibility of 1918 pandemic influenza. Nature 432, 904-906. (doi:10.1038/nature03063)
19. Ferguson, N., Mallet, S., Jackson, H., Roberts, N. &Ward, P. 2003 A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 51, 977-990. (doi:10.1093/jac/dkg136)
20. Towers, S. & Feng, Z. 2009 Pandemic H1N1 influenza: predicting the course of a pandemic and assessing the efficacy of the planned vaccination programme in the United States. Eurosurveillance 14, 6-8.
21. Chow, A., Ma, S., Ling, A. E. & Chew, S. K. 2006 Influenza- associated deaths in the tropical Singapore. Emerg. Infect. Dis. 12, 114-121. (Pubitemid 43143546)
22. Greenberg, M. E. et al. 2009 Response to a monovalent influenza A (H1N1) 2009 vaccine. N. Engl. J. Med. 361, 2405-2413. (doi:10.1056/NEJMoa0907413)
23. Murray, C. J. L., Lopez, A.D.,Chin, B.,Feehan, D.&Hill, K. H. 2006 Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 368, 2211-2218. (doi:10.1016/S0140-6736(06)69895-4)
24. Koopmanschap, M. A., Rutten, F. F. H., Vanineveld, B. M. & Vanroijen, L. 1995 The friction cost method for measuring indirect costs of disease. J. Health Econ. 14, 171-189. (doi:10.1016/0167-6296(94)00044-5)
25. Sachs, J. D. 2001. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, Switzerland. See http://www.whqlibdoc.who. int/publications/2001/924154550X.pdf.
26. Mengewein 2009 Roche cuts Tamiflu price for developing countries. Dow Jones Newswires/Wall Street Journal reports (Mengewein 7/1). 2 July 2009.
27. Lee,V. J. et al. 2010Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N. Engl. J. Med. 362, 2166-2174. (doi:10.1056/ NEJMoa0908482)
28. Jackson, H. C., Roberts, N., Wang, Z. M. & Belshe, R. 2000 Management of influenza - use of new antivirals and resistance in perspective. Clin. Drug Invest. 20, 447-454. (doi:10.2165/00044011-200020060-00007)
29. Lund, R. 2007 Revenge of the white swan. Am. Stat. 61, 189-192. (doi:10.1198/000313007X219374)
30. Taleb, N. N. 2007 The black swan: the impact of the highly improbable. New York, NY: Random House.
31. Nordhaus, W. 2007 Critical assumptions in the Stern review on climate change. Science 317, 201-202. (doi:10.1126/science.1137316)
32. Cooper, B., Pitman, R., Edmunds, W. & Gay, N. 2006 Delaying the international spread of a pandemic influenza. PLoS Med. 3, e212. (doi:10.1371/journal.pmed.0030212)